tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Immix Biopharma announces ‘class-leading’ safety profile for NXC-201
PremiumThe FlyImmix Biopharma announces ‘class-leading’ safety profile for NXC-201
3M ago
Immix Biopharma’s Strategic Expansion and Promising Trial Results Reinforce Buy Rating
Premium
Ratings
Immix Biopharma’s Strategic Expansion and Promising Trial Results Reinforce Buy Rating
3M ago
Immix Biopharma announces accelerated NEXICART-2 trial progress
Premium
The Fly
Immix Biopharma announces accelerated NEXICART-2 trial progress
3M ago
Immix Biopharma announces NXC-201 trial met primary endpoint
PremiumThe FlyImmix Biopharma announces NXC-201 trial met primary endpoint
4M ago
Immix Biopharma expands U.S. clinical sites for NEXICART-2 trial
Premium
The Fly
Immix Biopharma expands U.S. clinical sites for NEXICART-2 trial
5M ago
Buy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201
Premium
Ratings
Buy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201
8M ago
Immix Biopharma reports 75% CRR for NXC-201 in r/r AL amyloidosis patients
PremiumThe FlyImmix Biopharma reports 75% CRR for NXC-201 in r/r AL amyloidosis patients
10M ago
Immix Biopharma: Ex-US study of NXC-201 produced 92% ORR in r/r AL Amyloidosis
Premium
The Fly
Immix Biopharma: Ex-US study of NXC-201 produced 92% ORR in r/r AL Amyloidosis
1y ago
Immix Biopharma announces three more sites for NEXICART-2 trial
Premium
The Fly
Immix Biopharma announces three more sites for NEXICART-2 trial
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100